Pharminent

FDA panel backs Novartis’ CAR-T therapy CTL019

Novartis’ CTL019 has taken a giant leap towards the finishing line in the race to get the first cancer killing CAR-T cell therapy on the market having won the support of an FDA advisory panel. http://www.pharmatimes.com/news/fda_panel_backs_novartis_car-t_therapy_ctl019_1198432

Filed under: Cancer, Immunotherapy

Celgene joins PD-1 race via partnership with BeiGene

The pharma giant will pay the Chinese firm up to $980m in milestone payments http://www.pmlive.com/pharma_news/celgene_joins_pd-1_race_via_partnership_with_beigene_1197746

Filed under: Cancer, Immunotherapy

Merck Ventures creates new immuno-oncology company iOnctura

Merck, a leading science and technology company, today announced its corporate venture arm Merck Ventures created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Merck and three assets from Cancer Research Technology (CRT). http://www.worldpharmanews.com/merckgroup/3986-merck-ventures-creates-new-immuno-oncology-company-ionctura

Filed under: Cancer, Immunotherapy

Approval for biomarker-based Keytruda a US FDA first

US FDA has approved a cancer treatment based on a common biomarker, as opposed to the location in the body where the tumour developed. http://www.in-pharmatechnologist.com/Regulatory-Safety/Approval-for-biomarker-based-Keytruda-a-US-FDA-first

Filed under: Cancer, Immunotherapy

Updated NSCLC Guidelines Incorporate PD-L1 Testing and Molecular Assays

http://www.onclive.com/publications/oncology-live/2017/vol-18-no-11/updated-nsclc-guidelines-incorporate-pdl1-testing-and-molecular-assays

Filed under: Cancer, Immunotherapy

FDA clears Merck’s Keytruda for cancer patients with certain biomarkers

(Reuters) – The U.S. Food and Drug Administration on Tuesday approved Merck & Co’s immuno-oncology treatment, Keytruda, for cancer patients who carry a specific genetic feature.

http://www.reuters.com/article/us-merck-co-fda-idUSKBN18J2T9

Filed under: Cancer, Immunotherapy

Roche builds case for T-cell bispecific-anti-PD-L1 combo

Roche has published early clinical data on its bispecific antibody in heavily pretreated patients with metastatic colorectal cancer. The readout hints that the T cell-activating antibody may improve outcomes in this hard-to-treat population when given as a monotherapy and in combination with anti-PD-L1 drug Tecentriq. http://www.fiercebiotech.com/biotech/roche-builds-case-for-t-cell-bispecific-anti-pd-l1-combo

Filed under: Cancer, Immunotherapy

Merck’s Keytruda in combination with chemotherapy gets FDA nod to treat NSCLC

Merck’s Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) and carboplatin (pem/carbo) has been approved by the US Food and Drug Administration (FDA) for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. http://www.pharmaceutical-business-review.com/news/mercks-keytruda-regimen-gets-fda-approval-for-metastatic-nsclc-treatment-110517-5811043

Filed under: Cancer, Immunotherapy

Novartis licenses CAR-T patents from Celyad

Celyad has granted Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents. http://contractservices.pharmaceutical-business-review.com/news/celyad-grants-non-exclusive-license-for-allogeneic-tcr-deficient-car-t-cells-patents-to-novartis-030517-5803243

Filed under: Cancer, Immunotherapy

Immunotherapy Agents, Combinations to Compete for Frontline NSCLC

Sukhami Padda, MD, discusses the status of ongoing clinical trials participating in this race to the frontline setting in lung cancer. http://www.onclive.com/web-exclusives/immunotherapy-agents-combinations-to-compete-for-frontline-nsclc

Filed under: Cancer, Immunotherapy

Boehringer looks to cancer immunotherapy combinations

BI developing combinations with its own checkpoint inhibitors
The post Boehringer looks to cancer immunotherapy combinations appeared first on Pharmaphorum. http://pharmaphorum.com/news/boehringer-looking-cancer-immunotherapy-combos/

Filed under: Cancer, Immunotherapy

FDA Grants Priority Review to Novartis’s CAR-T Cell Therapy

NewsThe priority review designation is expected to shorten the anticipated review time by the FDA.Topics: Drug Pipeline http://www.dddmag.com/news/2017/03/fda-grants-priority-review-novartiss-car-t-cell-therapy

Filed under: Cancer, Immunotherapy

PD-1 and IDO Inhibitor Combo Slated to Change Practice in Melanoma

Thomas F. Gajewski, MD, PhD, discusses how the combination of PD-1 and IDO inhibitors could change the standard of care for patients with melanoma, and highlights other emerging targets on the horizon. http://www.onclive.com/web-exclusives/pd1-and-ido-inhibitor-combo-slated-to-change-practice-in-melanoma

Filed under: Cancer, Immunotherapy

Servier cleared to start US trials CAR-T therapy

FDA rules studies of its Pfizer-partnered drug can be resumed http://www.pmlive.com/pharma_news/servier_cleared_to_start_us_trials_car-t_therapy_1188731

Filed under: Cancer, Immunotherapy

Immunotherapy Companies Leading the Charge for Treating Cancer

NEW YORK, February 21, 2017 /PRNewswire/ — Immuno-oncology is one of the fastest growing and promising areas of cancer research. It is the genesis behind the rapidly expanding field of precision-focused cancer drug development. Immuno-oncology therapeutics is transforming the way… http://www.prnewswire.com/news-releases/immunotherapy-companies-leading-the-charge-for-treating-cancer-614345683.html

Filed under: Cancer, Immunotherapy

Immunotherapy Tops Cancer Advances Again

(MedPage Today) — Current, ongoing, future advances featured in ASCO report http://www.medpagetoday.com/publichealthpolicy/publichealth/62866

Filed under: Cancer, Immunotherapy

AstraZeneca expands 1st-line lung cancer Immuno-Oncology programme opportunities

AstraZeneca has provided an update on its Immuno-Oncology (IO) late-stage clinical development programme in 1st-line non-small cell lung cancer (NSCLC), including a refinement of the Phase III MYSTIC trial. The MYSTIC trial was initially designed to assess the benefit of durvalumab monotherapy and durvalumab and tremelimumab (durva + treme) combination therapy versus http://www.worldpharmanews.com/astrazeneca/3776-astrazeneca-expands-1st-line-lung-cancer-immuno-oncology-programme-opportunities

Filed under: Cancer, Immunotherapy

Kite inks China, Japan deals ahead of possible CAR-T drug approval

Through a joint venture with China’s Fosun Pharma, the CAR-T specialist gains a foothold for its lead drug candidate in the world’s second biggest pharmaceutical market. http://www.biopharmadive.com/news/Kite-Fosun-Car-T-China/433737/

Filed under: Cancer, Immunotherapy

Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance

[Marketwired] – Pieris and Servier, an independent international pharmaceutical company headquartered in France with annual sales of more than EUR4 billion, to jointly pursue several bispecific therapeutic programs including … http://finance.yahoo.com/news/pieris-pharmaceuticals-servier-forge-strategic-120000715.html

Filed under: Cancer, Immunotherapy

Merck kicks off consumer campaign for Keytruda

On the heels of Keytruda’s approval in first-line lung cancer, the drugmaker kicked off an unbranded campaign raising awareness about on biomarkers. http://www.mmm-online.com/campaigns/merck-kicks-off-consumer-campaign-for-keytruda/article/578357/

Filed under: Cancer, Immunotherapy

Categories